NASDAQ$KLRS
Kalaris Therapeutics Inc · Q4 2022 earnings
Q4 2022 earnings · · Investor relations
Briefing
AlloVir reported full-year financial results and provided 2023 outlook.
AlloVir reported its full-year 2022 financial results, highlighting the progress of its allogeneic, off-the-shelf, virus-specific T cell (VST) programs and providing an outlook for 2023 and into 2024. The company's cash position remains strong, with $233.8 million as of year-end 2022.
- Enrollment completion of all three posoleucel Phase 3 registrational trials is expected by the end of 2023, with data readouts in 2024.
- Positive final results were announced from a Phase 2 study of posoleucel in kidney transplant recipients with BK viremia.
- The company plans to complete enrollment in its Phase 3 registrational studies during 2023, enabling data readouts in 2024.
- Final data from a Phase 2 study evaluating posoleucel for the prevention of clinically significant viral infections in allo-HCT patients was presented at the ASH Annual Meeting and Exposition in December 2022.
Headline financials
Revenue & EPS history
Allovir · Revenue · Quarterly
$0
Forward guidance
AlloVir anticipates completing enrollment in Phase 3 registrational trials by the end of 2023, which would enable data readouts in 2024. For fiscal year 2023, AlloVir expects operating expenses to be in the range of $150 million to $170 million, excluding non-cash expenses.
Tailwinds
- Completion of enrollment of all three posoleucel Phase 3 registrational trials anticipated by end of 2023
- Data readouts in 2024
- Global enrollment is ongoing in Phase 3 studies of posoleucel for the treatment of virus-associated hemorrhagic cystitis and adenovirus infection.
- Both studies are expected to complete enrollment by year-end 2023, with topline data anticipated in 2024.
- The company plans to present comprehensive results from the BKV Phase 2 study at a scientific congress later this year.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2022
+0.5%
Avg return
Earnings day
+0.4%
Avg return
5 days after
+5.9%
Avg return
30 days after
50%
11 / 22 earnings
Positive
+33.6%
Q2 2022
Best reaction
-23.8%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q3 2025 | -1.8% | +6.9% | +75.0% | |
| Q2 2025 | -10.9% | +0.4% | +56.2% | |
| Q2 2024 | -3.3% | -5.7% | +75.0% | |
| Q1 2025 | -6.1% | -2.8% | +5.6% | |
| Q4 2025 | -3.4% | +4.2% | -21.2% | |
| Q3 2024 | -23.8% | -23.0% | -37.8% | |
| Q1 2024 | -1.7% | -1.4% | +0.5% | |
| Q4 2023 | +0.7% | +2.5% | +5.5% | |
| Q3 2023 | +9.1% | +9.1% | +27.9% | |
| Q2 2023 | +3.0% | +0.3% | +6.6% | |
| Q1 2023 | +14.2% | +13.0% | +2.6% | |
| Q4 2022 | -6.1% | +5.5% | -30.9% | |
| Q3 2022 | +0.9% | +9.1% | +10.5% | |
| Q2 2022 | +33.6% | +37.7% | +31.7% | |
| Q1 2022 | +0.4% | -23.8% | -25.3% | |
| Q4 2021 | +2.3% | +3.6% | -14.1% | |
| Q3 2021 | -2.3% | -3.0% | -28.9% | |
| Q2 2021 | +6.1% | +0.6% | +0.0% | |
| Q1 2021 | +9.7% | +5.0% | +6.0% | |
| Q4 2020 | +0.5% | -2.5% | -29.4% | |
| Q3 2020 | -0.5% | -6.3% | +24.2% | |
| Q2 2020 | -9.7% | -20.6% | -9.5% | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro